By 2020, pancreatic cancer is predicted to become the second leading cause of cancer-related death in the United States. We are developing a Point of Care Testing for sporadic Pancreatic Ductal Adenocarcinoma screening, based on a routine and non-invasive urine biopsy ready to detect high sensitivity and specificity PDAC biomarkers. 

Meet the team.

The following people are part of the National Scientific and Technical Research Council, the University of Buenos Aires and the National University of San Martin and work with the assistance of Sanatorio Otamendi & Miroli S.A. and Weinvent Innovation Lab.